The Comparison of Medical Therapy, Pacing and Defibrillation in Chronic Heart Failure (COMPANION) trial has been halted by the data safety and monitoring board because patients in the active treatment arm of the study have had a significant reduction in all-cause mortality and hospitalization. In the study involving 1,600 high-risk patients with moderate to severe heart failure and QRS complexes longer than 120 ms and P-R intervals greater than 150 ms, subjects were randomized to one of three arms.
While all patients received maximal medical therapy, one group received that plus resynchronization therapy with Guidant Corp.’s Contak TR device, and a third received resynchronization therapy plus defibrillation as necessary with the Contak CD device.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!